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SUMMARY (250 words) 
Background Chest computerized tomography (CT) scores are associated with the frequency of future 
pulmonary exacerbations in people with cystic fibrosis (CF). However, cut-off values to identify children with 
mild lung disease with different risks for frequent future pulmonary exacerbations have not been identified. 
Methods Chest CT scans were assessed using the Brody score for participants of the Pulmozyme Early 
Intervention Trial (PEIT) and Wisconsin Randomized Clinical Trial of CF Newborn Screening (WI RCT). We 
determined the area under the receiver operating characteristic (ROC) curve for Brody scores and forced 
expiratory volume in 1 second (FEV1) to compare with the frequency of pulmonary exacerbations up to 10 
years later.  
Results There were 60 participants in the PEIT with mean (SD) age 10.6 (1.7) years at the time of the CT and 
81 participants in the WI RCT with mean age 11.5 (3.0) years. The Brody score cut-off that best identified 
children at-risk for ≥0.3 annual pulmonary exacerbations was 3.6 in the PEIT and 2.1 in the WI RCT. There 
were no statistical differences between ROC curves for the Brody CT score and FEV1 % predicted in either 
study (p ≥0.4). 
Conclusions CT score cut-off values that identify children with CF with mild lung disease at different risks for 
frequent pulmonary exacerbations over an extended follow up period are similar in separate cohorts. Brody 
scores and FEV1 % predicted have similar abilities to identify these children, suggesting that FEV1 % predicted 
alone may be adequate for predicting future frequency of pulmonary exacerbations.  
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INTRODUCTION  
Computerized tomography (CT) scans of the chest are used in research and clinical practice to detect the 
severity of structural lung disease in people with cystic fibrosis (CF). Chest CT scores are sensitive to detect 
early, regional disease, and are more sensitive to progression of disease than traditional spirometry.1-3 Chest CT 
scores are also predictive of the frequency of future pulmonary exacerbations up to 10 years later.4-6 This 
predictive ability is important because pulmonary exacerbations are valuable clinical endpoints associated with 
lower quality of life, increased healthcare costs, more rapid progression of lung disease, and increased 
mortality.7-11 Patients at high risk could be treated with additional CF therapies that have been shown to reduce 
the frequency of pulmonary exacerbations, and efforts could be made to increase adherence to CF therapies, as 
better adherence is associated with lower rates of pulmonary exacerbations.12 Conversely, decreasing the burden 
of care for patients who are at low risk of having pulmonary exacerbations by decreasing the number of 
therapies would be helpful in reducing healthcare costs and improving adherence and quality of life.13  
Cut-off values that can differentiate between children with CF who are at high- or low-risk for future pulmonary 
exacerbations have been described. Loeve et al. compared the rates of pulmonary exacerbations in the two years 
after a chest CT scan was obtained.4 They found that subjects with bronchiectasis scores >7% of the maximum 
score were more likely to have at least one exacerbation during two years of follow up. They also found that the 
rate of pulmonary exacerbations was significantly higher for children with forced expiratory volume in 1 second 
(FEV1) ≤78% predicted, but did not compare the predictive ability of chest CT scores to FEV1. Another study 
from the same group found that subjects who had bronchiectasis scores >17.5% of the maximum score were 
more likely to have more than 3 exacerbations in a 6 year follow up period.6 The cut off for FEV1 obtained at 
the same time as the chest CT did not perform as well as bronchiectasis in identifying these patients.  
These cut-points, however, will have limited clinical utility at this time, as children with CF today are unlikely 
to average 2 pulmonary exacerbations per year or to have bronchiectasis this severe.14,15 Determining whether 
specific cut-off values in chest CT scores can identify a particular patient’s risk of future pulmonary 
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exacerbations in a cohort of healthier children with CF would provide a better assessment of the value of CT 
scanning in predicting future disease severity. Clinical decision making tools that identify patients with high 
risk for future morbidity or mortality have been successfully developed in other pulmonary disorders such as 
asthma, community acquired pneumonia, and COPD.16-18 There are no widely used clinical prediction tools in 
CF. A recently developed tool for predicting future spirometry does not include chest CT results.19 Our 
hypothesis is that meaningful cut-off values in the Brody chest CT score can be identified that will identify 
children with CF at high- or low-risk for frequent future pulmonary exacerbations, and that the cut-off points 
will provide more predictive ability than FEV1 % predicted. To address our hypothesis, we compared the rates 
of pulmonary exacerbations for up to 10 years after chest CT scans were obtained in two well-defined cohorts 
of children with CF.  
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MATERIALS AND METHODS 
Study cohorts 
Longitudinal data were obtained for two distinct cohorts of children with CF. The first cohort includes children 
in the Pulmozyme Early Intervention Trial (PEIT).20  The inclusion criteria for the PEIT were: children with 
CF, ages 6-10 years, with forced vital capacity (FVC) ≥85% predicted, the ability to perform reproducible 
pulmonary function tests, no dornase alpha use for 6 months prior to enrollment, and no pulmonary 
exacerbations within 60 days prior to enrollment. Chest CT scans were obtained in 1999-2000 for 60 of the 
subjects in the PEIT at 15 participating centers during periods of clinical stability at the end of the 2-year study 
and scored using the Brody scoring system.21 Spirometry was performed on the same day as the chest CT. Data 
from the time of the chest CT through the last available data entry or 2009, whichever came first, was obtained 
from the CF Foundation Patient Registry (CFFPR) and linked to the original chest CT data. The CFFPR is a 
well-described database that contains detailed data on demographics  at every encounter for people with CF in 
the U.S.22 Pulmonary exacerbations treated with IV antibiotics (at home or in the hospital) for an increase in 
respiratory signs and symptoms were recorded in the CFFPR.  
The second cohort includes subjects in the well described Wisconsin Randomized Clinical Trial of CF Newborn 
Screening (WI RCT).23 In summary, blood specimens of newborns born in Wisconsin between 1985 and 1994 
were assigned either to an early CF diagnosis group or to a standard diagnosis group. Children  in both groups 
were diagnosed with CF with a sweat chloride level ≥60 mEq/L and were seen every 3 months and 
prospectively followed in the study through age 21, or 6/30/2010, whichever was earlier.23 Cultures of 
respiratory secretions were obtained quarterly. Spirometry was obtained at least every 6 months with strict 
quality control measures.24 A chest CT was added in 2000 for patients who continued to receive care in the 
protocol and who gave additional informed consent, as described previously.25 We recorded the FEV1 % 
predicted obtained closest to the chest CT (within one year prior). As in the PEIT study, pulmonary 
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exacerbations treated with IV antibiotics for an increase in respiratory signs and symptoms were recorded for 10 
years or through 6/30/2010, whichever came earlier. 
Chest CT protocols 
In the PEIT study, CT scans were obtained according to a protocol that used 1 mm thick slices and a 1 second 
scan time. Inspiratory images were obtained at 10-mm intervals and 4 expiratory images were obtained at: 0.5 
cm above the aortic arch, the carina, at the inferior margin of the hilum, and 1 cm above the diaphragm. CT 
scans were scored independently by two thoracic radiologists using the Brody scoring system.21 In the WI RCT 
study, after the recent history, physical examination, and spirometry were reviewed to determine they were at 
their baseline health status, a chest CT was performed. The CT scan (Lightspeed; GE Medical Systems, 
Milwaukee) protocol used 1.25-mm thick slices with inspiratory images at 10 mm intervals and expiratory 
images at 20 mm intervals. Hard-copy images were scored independently by three radiologists (ASB and two 
others) using the Brody scoring system.25  
In both studies, the radiologists were blinded to the patient identities, severity of lung disease, and 
randomization group. The Brody scoring system has been reported as a total score with a maximum possible 
value of 20721 and as a score representing the average severity of each of the six lobes, including the lingula as a 
separate lobe, with a maximum of 40.5.26 For this analysis, we report Brody scores using the latter method. 
Statistical Analysis 
We used descriptive statistics to describe both of the cohorts at the time of the chest CT and at the most recent 
follow up point. In the US, approximately 1 in 3 children with CF are treated with IV antibiotics for a 
pulmonary exacerbation each year.27 For our initial analysis, we compared children who had an annual rate 
above the median rate of pulmonary exacerbations of 0.3 pulmonary exacerbations per year to children who had 
fewer pulmonary exacerbations. The risk of pulmonary exacerbations treated with IV antibiotics increases with 
age,9 but not in a uniform fashion, so for this analysis we averaged the total number of pulmonary exacerbations 
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over the observation period. All analyses were performed separately for the PEIT and WI RCT cohorts to assess 
the generalizability of our results. To determine the cut-off points which best discriminate between these rates 
of pulmonary exacerbations, we obtained the area under the receiver operating characteristic (ROC) curve 
(AUC), and values for sensitivity and specificity were calculated. A comparison of AUCs was performed using 
the chi-square test of Wald statistics comparing the Brody CT score and bronchiectasis subscores to FEV1 % 
predicted. We then determined the annual rate of pulmonary exacerbations per year and compared children at 
high-risk (defined as the top quartile of pulmonary exacerbations) and low-risk (defined as the bottom quartile 
of pulmonary exacerbations) to the children in the remaining three quartiles in both PEIT and WI RCT study 
cohorts. Statistical significance was defined as a two-sided p-value < 0.05. The current study was approved by 
the IRBs at the University of Cincinnati and University of Wisconsin. 
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RESULTS 
The demographics and characteristics of the children in the PEIT and WI RCT cohorts were similar (Table 1). 
At the time of the CT, which occurred between 1999 and 2000 for both cohorts, there were more children in the 
PEIT study who were pancreatic insufficient (p = 0.016) and infected with Staphylococcus aureus (p = 0.009); 
mean FEV1 % predicted was higher than in the WI RCT cohort (p = 0.003). One patient in the PEIT study was 
positive for methicillin resistant S. aureus at the time of the chest CT; there were none in the WI RCT cohort. In 
the PEIT study, the mean (SD) Brody chest CT score was 3.8 (1.9) out of a possible 40.5. The mean (SD) 
bronchiectasis subscore was 0.6 (0.8) out of a possible 12. In the WI RCT study, the mean (SD) Brody chest CT 
score was 3.1 (2.9), and the mean (SD) bronchiectasis subscore was 1.0 (1.2). Each of these scores indicates 
generally mild, but abnormal, values.  
Data were missing for a very small percentage of the overall cohort. Data were available in the CFFPR for all 
participants in the PEIT study for 5 years after the chest CT, and for 55 subjects up to 10 years later. One patient 
died prior to 2009. Overall, the mean (SD) observation time after the chest CT was 9.8 (0.7) years. For the WI 
RCT study, the mean observation time between the chest CT scan and the most recent observation was 7.5 
years. No patients died before the end of the study period. The decline in FEV1 % predicted was greater for the 
participants of the PEIT study (-2.2% predicted per year) than for the participants of the WI RCT study (-0.6% 
predicted per year), p < 0.001. More participants in the PEIT study acquired Pseudomonas aeruginosa during 
the follow up period than in the WI RCT study, p = 0.0015 (Table 1). During the observation period, the range 
of pulmonary exacerbations treated with IV antibiotics and recorded in the CFFPR was 0 to 63 for participants 
in the PEIT study and 0 to 50 for participants in the WI RCT study (Figure 1). The median annual rate of 
pulmonary exacerbations was 0.35 for participants in the PEIT study and 0.30 for participants in the WI RCT 
study.  
The mean Brody chest CT scores, bronchiectasis subscores, and FEV1 % predicted were all statistically 
significantly different between children with ≥0.3 pulmonary exacerbations or <0.3 pulmonary exacerbations 
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per year in both the PEIT and WI RCT studies, and when combining the two studies (Table 2). Results were 
similar when using medians instead of means (data not shown). The differences in the mean FEV1 % predicted 
(~12% predicted), Brody CT score (~ 2 points), and bronchiectasis subscore (~0.7 points) between the 
pulmonary exacerbation groups were similar in the PEIT and WI RCT cohorts. The optimal cut-off points to 
differentiate between the frequencies of future pulmonary exacerbations were similar in the PEIT and WI RCT 
cohorts for FEV1 % predicted (94.1-101.6), the Brody chest CT score (2.1-3.6), and bronchiectasis subscore 
(0.3-0.4) (Table 3). The AUCs were also similar between the two studies for each of the lung disease measures. 
FEV1 % predicted had a higher AUC in the PEIT study than in the WI RCT study. The AUCs were not 
substantially affected when we adjusted for P. aeruginosa, BMI below the 10th percentile, or Medicaid 
insurance status at the time of the CT in bivariate analyses (data not shown). There were no statistical 
differences between the ROC curves for the Brody CT score and FEV1 % predicted in the PEIT study (p = 0.6), 
WI RCT study (p = 0.4), or the combined studies (p = 0.8) (Figure 2). The differences between the 
bronchiectasis subscore and FEV1 % predicted were also not statistically significantly different (data not 
shown).  
The sensitivities and specificities for each of these measures of lung disease were similar between the two 
studies (Table 4); only FEV1 % predicted was more sensitive and specific in the PEIT study in comparison to 
the WI RCT study. Combining the cohorts did not improve sensitivity or specificity. We also tested whether 
combining the cut-off values for FEV1 % predicted and the Brody score changed the sensitivity and specificity. 
In both cohorts, the sensitivity for identifying children at risk of frequent future pulmonary exacerbations 
increased, but the specificity decreased (Table 4). The corresponding mean (95% CI) AUC in the PEIT study, 
0.85 (0.75, 0.94), was increased in comparison to the AUC for FEV1 % predicted alone, 0.79 (0.68, 0.90), but 
the difference was not statistically significant (p = 0.18). Similarly in the WI RCT study, the AUC for FEV1 % 
predicted combined with the Brody score was 0.75 (0.63, 0.86), compared to 0.67 (0.55, 0.79) for FEV1 % 
predicted alone, p = 0.14. 
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We repeated our analyses by comparing the children with the highest and lowest quartiles of pulmonary 
exacerbation rates in each cohort (Table 5). In general, the optimal cut-off points, AUCs, sensitivities, and 
specificities to differentiate between the frequencies of future pulmonary exacerbations were similar when 
comparing children above and below the median and lowest quartile rate of pulmonary exacerbations. Children 
with the highest quartile rate of pulmonary exacerbations (>1 per year) had slightly lower FEV1 % predicted 
and higher Brody CT scores. The Brody CT score had slightly better AUCs than FEV1 % predicted for 
identifying the children with the highest quartile rate of pulmonary exacerbations. There were no statistical 
differences between the ROC curves for the Brody CT score or FEV1 % predicted when combining the two 
studies when we changed the annual rate of pulmonary exacerbations to 0.4 per year (p = 0.5) or 0.5 per year (p 
= 0.7). 
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DISCUSSION 
This study identifies cut-off values in the Brody CT score that distinguish between children with essentially 
normal values for FEV1 % predicted who went on to have different rates of pulmonary exacerbations up to 10 
years later in two separate cohorts of children with CF. Neither Brody CT scores nor bronchiectasis subscores 
distinguished between the two groups of children better than FEV1 % predicted obtained at the same time as the 
chest CT. This was true whether the CT score was used alone, or in combination with FEV1 % predicted. By 
defining cut-off values that are similar in different cohorts of children with CF with mild lung disease on 
spirometry and chest CT, our results add to our understanding of CT scores as surrogate endpoints. Most 
importantly, our results suggest that the risk of future pulmonary exacerbations treated with IV antibiotics is not 
negligible even among the majority of children with CF today who have normal spirometry and minimal 
structural lung disease. 
 
Predictive ability of chest CT scores 
Similar to previous studies, we have demonstrated an association between chest CT scores and future risk or 
frequency of pulmonary exacerbation,3,4,6,31 though we did not find an optimal cut-point that could meaningfully 
distinguish patients at high- or low-risk of future pulmonary exacerbations. In the study by Botoluzzi and 
colleagues, the optimal cut point to identify patients with more than 3 exacerbations over 6 years of follow up 
was a bronchiectasis score of 17.5%.6 In the study by Loeve et al., bronchiectasis subscores >7% identified 
children with ≥0.5 annual pulmonary exacerbations in a 2-year follow up period.4 Our results build on these 
previous studies by demonstrating the link in healthier children with less bronchiectasis and fewer pulmonary 
exacerbations, and over a longer follow up period. Expressed as a percentage, the best cut-point for the 
bronchiectasis subscore in our studies were lower at 2.5% and 3.3%. Our results are further strengthened by 
using data from two multi-center studies. Taken together, our results may be more generalizable to current 
cohorts of children with CF.  
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Predictive ability of CT scores compared to FEV1 
Our results demonstrate a single CT score and FEV1 measurement have predictive abilities in multiple cohorts 
comparable to the ability of FEV1 to predict 2-year mortality.28 In contrast to chest CT scores, more information 
is available on clinically important cut-off values for FEV1 % predicted that would allow clinicians to identify 
children with CF who are at high risk for future adverse events. The lower limit of normal for FEV1 % predicted 
has been defined according to age and sex for global populations,32 and in comparison to other children with 
CF.33 However, it is unclear what degree of abnormalities on chest CT is indicative of future morbidity and 
mortality. Although chest CT is much more sensitive than FEV1 in detecting progression of early CF lung 
disease, in our study, FEV1 % predicted was as effective as chest CT scores in identifying children at risk for 
frequent future pulmonary exacerbations. When we compared the optimal cut-points for identifying the 25% of 
patients with the least and most pulmonary exacerbations, neither the Brody CT score nor bronchiectasis 
subscore performed better than FEV1 % predicted, though the Brody CT score tended to perform slightly better 
in identifying the children with the most pulmonary exacerbations. In contrast, CT scores generally performed 
better than FEV1 in the studies by Bortoluzzi and Loeve.4,6 Studies of potential predictors of disease progression 
are highly dependent on characteristics of the study cohort and frequency of the outcome measure (i.e., 
pulmonary exacerbations). There are many differences between our study and previous studies that may 
potentially explain the different results, including different patient populations with different severities of lung 
disease, study designs (single- vs multi-center, exacerbation frequency cut-point), and purpose for obtaining CT 
scans (clinical vs research). Given the high correlation between FEV1 and the rate of pulmonary exacerbations,9 
it is not surprising that FEV1 would be associated with future risk of pulmonary exacerbations. As FEV1 
increases for subsequent birth cohorts of children with CF, and as FEV1 decline slows over time,34 other 
evaluation methods that are more sensitive, e.g., CT scores, lung clearance index,35 or magnetic resonance 
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imaging,36 may be needed to identify children at risk for adverse clinical outcomes. Further work is necessary to 
meaningfully use this predictive ability to adjust therapeutic regimens. 
 
Risk of pulmonary exacerbations 
We also note that pulmonary exacerbations occurred frequently during the follow up period in these two 
relatively healthy cohorts of children with CF. The proportion of children with at least one pulmonary 
exacerbation treated with IV antibiotics per year is between 20 and 30% for ages 5-13 years, and has not 
changed appreciably in at least 20 years.27 Although the use of CFTR modulators decreases the frequency of 
pulmonary exacerbations, patients continue to be at-risk for loss of FEV1 following these events.37 It is 
imperative that we identify patients at-risk for pulmonary exacerbations to prevent the occurrence of these 
important patient-centered outcomes. Our analysis was not designed to address the ability of FEV1 or chest CT 
to predict pulmonary exacerbations over a short time span, which can contribute substantially to progression of 
lung disease.38,39 A history of pulmonary exacerbations treated with IV antibiotics is highly predictive of future 
risk of pulmonary exacerbations.40  
 
Limitations 
The chest CT scans in the PEIT and WI RCT studies were obtained, on average, at about 10 years of age, so we 
are unable to comment on the generalizability of cut-off values in CT scores, either in terms of age, severity of 
FEV1, or predictive ability. We did not assess chronic medication use in this analysis, although eligible patients 
not taking chronic medications are at increased risk for pulmonary exacerbations over a short time frame.41 In 
order to attain a long follow up period, we studied outcomes after chest CT scans that were obtained in 1999-
2000, before many of the current CF therapies were available. As with any study with a long follow up period, 
this could limit the generalizability of our findings and the ability to predict future events, especially as 
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additional therapies become available. Given the long follow up period, it is not entirely surprising that the 
AUC values were only “acceptable,” i.e., not “excellent” or “outstanding.”42 Ongoing studies that incorporate 
serial chest CT scans may provide additional information on the predictive ability of chest CT findings, 
especially in younger children with mild lung disease.43,44  
Prior to 2012, pulmonary exacerbations treated without IV antibiotics were not recorded in the CFFPR, so our 
study cannot assess if spirometry or quantitative chest CT scores are associated with the future risk of these 
pulmonary exacerbations, which are likely more common in our study population made of young patients with 
high levels of lung function.45 The Brody score is a research tool that is challenging to use in routine clinical 
care at this time to adjust therapeutic regimens.46 Given the probability that quantitative chest imaging will be 
clinically valuable,24,31 current efforts are ongoing to develop an automated scoring system.47,48 However, 
currently there are no data that show that alterations in care based on routinely obtained CT scans result in 
improved outcomes.  
 
Conclusions 
We have defined cut-off points in Brody scores that discriminate between children with CF and mild lung 
disease at different risks for frequent future pulmonary exacerbations over an extended follow up period. Brody 
scores were relatively similar in separate cohorts of children with CF with normal FEV1. Ongoing studies may 
be helpful in optimizing the use of chest CT scores for prediction of future disease progression in younger 
children with CF. 
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Figure Legends 
Figure 1. Annual rates of pulmonary exacerbations for the PEIT study, the WI RCT study, and the combined 
cohorts. 
 Figure 2. ROC curves to discriminate between <0.3 and ≥0.3 annual future pulmonary exacerbations for chest 
CT score and FEV1 % predicted in the PEIT study (A), WI RCT study (B), and combined cohorts (C).  
 
Table 1. Characteristics of the study cohorts.  
 PEIT Study cohort,  
N = 60 
WI RCT Study cohort,  
N = 81 
Combined,  
N=141 
Patient Characteristic At time of 
chest CT 
At follow up At time of 
chest CT 
At follow up At time of 
chest CT 
At follow up 
 n (%) or 
mean (SD) 
n (%) or 
mean (SD) 
n (%) or 
mean (SD) 
n (%) or 
mean (SD) 
n (%) or mean 
(SD) 
n (%) or 
mean (SD) 
Female sex 24 (40) 21 (38) 34 (42) 34 (42) 58 (41) 55 (40) 
Age, years 10.6 (1.7) 20.5 (1.7) 11.5 (3.0) 19.7 (1.6) 11.1 (2.5) 20.0 (1.7) 
Homozygous F508del 30 (50) 26 (47)  46 (57) 46 (57) 76 (54) 72 (53) 
Heterozygous F508del 23 (38) 22 (40) 31 (38) 31 (38) 54 (38) 53 (39) 
Other mutations 7 (12) 7 (13) 4 (5) 4 (5) 11 (8) 11 (8) 
Pancreatic insufficient 58 (97) 53 (96) 68 (84) 68 (84) 126 (89) 121 (89) 
FEV1 % predicted 99.2 (14.2) 77.1 (23.9) 91.1 (16.7) 86.4 (20.4) 94.6 (16.2) 82.6 (22.3) 
Culture positive for 
Pseudomonas aeruginosa 
30 (50) 39 (74) 39 (48) 33 (47) 69 (49) 72 (59) 
Culture positive for mucoid P. 
aeruginosa 
20 (33) 29 (55) 23 (28) 27 (39) 43 (31) 56 (46) 
Culture positive for 
Staphylococcus aureus 
40 (67) 24 (45) 36 (44) 41 (59) 76 (54) 65 (53) 
 
 Table 2. The difference in FEV1 % predicted, chest CT score, and bronchiectasis score that differentiates between the frequencies of future 
pulmonary exacerbations 
 PEIT Study cohort WI RCT Study cohort Combined 
Lung disease 
measure 
Annual frequency 
of pulmonary 
exacerbations 
  Annual frequency 
of pulmonary 
exacerbations 
  Annual frequency  
of pulmonary exacerbations 
 ≤0.3 
N=30 
(50%) 
>0.3 
N=30 
(50%) 
Difference, 
Mean (SD) 
P-
value 
≤0.3 
N=34 
(42%) 
>0.3 
N=47 
(58%) 
Difference, 
Mean (SD) 
P-
value 
≤0.3 
N=64 
(45%) 
>0.3 
N=77 
(55%) 
Difference, 
Mean (SD) 
P-
value 
Mean (SD) 
FEV1 % 
predicted 
106.3 
(11.1) 
92.2 
(13.6) 
14.1 (12.4) <0.001 97.2 
(11.4) 
86.7 
(18.8) 
10.5 (16.2) 0.003 101.7 
(12.0) 
88.9 
(17.0) 
12.8 
(15.0) 
<0.001 
Mean (SD) 
Brody CT score 
2.9 
(1.1) 
4.7 
(2.2) 
-1.8 (1.7) <0.001 1.9 
(1.9) 
4.0 
(3.2) 
-2.1 (2.7) <0.001 2.4 
(1.6) 
4.3  
(2.9) 
-1.9  
(2.4) 
<0.001 
Mean (SD) 
Bronchiectasis 
score 
0.3 
(0.4) 
0.9 
(1.0) 
-0.6 (0.8) 0.008 0.5 
(0.7) 
1.3 
(1.4) 
-0.8 (1.1) <0.001 0.4 
(0.6) 
1.2  
(1.2) 
-0.7 
 (1.0) 
<0.001 
 
 
  
  
Table 3. Optimum cut-off values and area under the curve (AUC) for FEV1 % predicted, chest CT score, and bronchiectasis score that differentiate 
between patients with ≤0.3 or >0.3 annual pulmonary exacerbations 
 PEIT Study cohort WI RCT Study cohort Combined 
Lung disease measure Optimal cut-
off  
Mean (95% CI) AUC Optimal cut-
off 
Mean (95% CI) AUC Optimal cut-
off 
Mean (95% CI) AUC 
FEV1 % predicted 101.6 0.79 (0.68, 0.90) 94.1 0.67 (0.55, 0.79) 95.9 0.72 (0.64, 0.80) 
Brody CT score 3.6 0.75 (0.62, 0.88) 1.9 0.74 (0.62, 0.85) 3.4 0.71 (0.62, 0.79) 
Bronchiectasis score 0.4 0.69 (0.56, 0.83) 0.3 0.73 (0.62, 0.85) 0.4 0.72 (0.63, 0.80)  
 
  
Table 4. Sensitivities and specificities for chest CT score, bronchiectasis score, FEV1 % predicted, and chest CT score combined with FEV1 % 
predicted for differentiating between patients with ≤0.3 and >0.3 annual future pulmonary exacerbations 
 PEIT Study cohort WI RCT Study cohort Combined 
Lung disease 
measure 
Sensitivity  Specificity Sensitivity  Specificity Sensitivity  Specificity 
FEV1 % predicted 0.77(.61,.93) 0.70(.53,.87) 0.62(.47,.77) 0.61(.43,.79) 0.61(.49,.73) 0.69(.57,.81) 
Brody CT score 0.70(.53,.87) 0.77(.61,.93) 0.68(.54,.82) 0.71(.54,.87) 0.55(.43,.66) 0.75(.64,.86) 
Bronchiectasis 
score 
0.60(.41,.79) 0.67(.49,.85) 0.72(.59,.86) 0.62(.45,.79) 0.61(.50,.72) 0.69(.57,.80) 
FEV1 % predicted + 
Brody CT score 
0.90(.79,1) 0.53(.34,.72) 0.85(.75,.96) 0.50(.32,.68) 0.74(.64,.84) 0.55(.42,.67) 
 
  
  
Table 5. Optimum cut-off values, area under the curve (AUC), sensitivities, and specificities for FEV1 % predicted, chest CT score, and 
bronchiectasis scores that differentiate between patients in the top and bottom quartile for annual rate of pulmonary exacerbations 
 Bottom quartile (0 pulmonary exacerbations per year) Top quartile (>1 pulmonary exacerbation per year) 
 FEV1 % predicted Brody CT score Bronchiectasis 
subscore 
FEV1 % predicted Brody CT score Bronchiectasis 
subscore 
 PEIT WI RCT PEIT WI RCT PEIT WI RCT PEIT WI RCT PEIT WI RCT PEIT WI RCT 
Optimal 
cut-point 
103.6 94.1 3.33 1.44 0.33 0.28 98.2 80.9 3.79 2.90 0.50 1.36 
AUC (95% 
CI) 
0.75 
(0.62, 
0.88) 
0.74 
(0.62, 
0.86) 
0.73 
(0.60, 
0.86) 
0.72 
(0.59, 
0.85) 
0.70 
(0.55, 
0.85) 
0.73 
(0.61, 
0.86) 
0.71 
(0.58, 
0.85) 
0.64 
(0.46, 
0.81) 
0.75 
(0.62, 
0.88) 
0.80 
(0.68, 
0.92) 
0.70 
(0.53, 
0.87) 
0.76 
(0.63, 
0.90) 
Sensitivity 0.75 0.78 0.81 0.65 0.81 0.70 0.73 0.57 0.73 0.81 0.67 0.67 
Specificity 0.73 0.62 0.59 0.69 0.57 0.67 0.62 0.84 0.67 0.73 0.69 0.84 
 
 
 




